DK2595485T3 - Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af sigma-receptormedierede forstyrrelser - Google Patents
Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af sigma-receptormedierede forstyrrelser Download PDFInfo
- Publication number
- DK2595485T3 DK2595485T3 DK11810350.6T DK11810350T DK2595485T3 DK 2595485 T3 DK2595485 T3 DK 2595485T3 DK 11810350 T DK11810350 T DK 11810350T DK 2595485 T3 DK2595485 T3 DK 2595485T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- treatment
- mediated disorders
- sigma receptor
- amid derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36608010P | 2010-07-20 | 2010-07-20 | |
| PCT/US2011/044698 WO2012012543A1 (en) | 2010-07-20 | 2011-07-20 | Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2595485T3 true DK2595485T3 (da) | 2022-05-30 |
Family
ID=45497167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11810350.6T DK2595485T3 (da) | 2010-07-20 | 2011-07-20 | Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af sigma-receptormedierede forstyrrelser |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20130274290A1 (da) |
| EP (2) | EP2595485B1 (da) |
| JP (3) | JP2013531073A (da) |
| KR (1) | KR101867634B1 (da) |
| CN (2) | CN107007603A (da) |
| BR (1) | BR112013001302A2 (da) |
| CA (2) | CA2805904C (da) |
| DK (1) | DK2595485T3 (da) |
| ES (1) | ES2914120T3 (da) |
| HU (1) | HUE058736T2 (da) |
| PL (1) | PL2595485T3 (da) |
| PT (1) | PT2595485T (da) |
| RU (2) | RU2613201C2 (da) |
| TW (1) | TWI520949B (da) |
| WO (1) | WO2012012543A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8937900B2 (en) | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| WO2015191554A1 (en) * | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| PT3227273T (pt) * | 2014-12-02 | 2022-04-06 | Minerva Neurosciences Inc | Composições que compreendem 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratamento de esquizofrenia |
| KR20240005110A (ko) * | 2016-05-25 | 2024-01-11 | 미쓰비시 타나베 파마 코퍼레이션 | 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법 |
| US11464744B2 (en) * | 2017-06-21 | 2022-10-11 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| MX2021002017A (es) * | 2018-08-21 | 2021-04-28 | Minerva Neurosciences Inc | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. |
| EP4153209A1 (en) | 2020-05-20 | 2023-03-29 | The Board of Trustees of the University of Illinois | Method for treating lysosomal storage diseases with histatin peptides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991006297A1 (en) * | 1989-10-27 | 1991-05-16 | The Du Pont Merck Pharmaceutical Company | (n-phthalimidoalkyl) piperidines |
| IE903857A1 (en) * | 1989-10-27 | 1991-05-08 | Du Pont Merck Pharma | (N-Phthalimidoalkyl)Piperidines |
| NZ251610A (en) * | 1992-04-23 | 1996-02-27 | Merrell Dow Pharma | 4-imidomethyl-1-(2-phenyl-2-oxoethyl)piperidine derivatives and pharmaceutical compositions |
| ES2291293T3 (es) * | 2000-02-29 | 2008-03-01 | Mitsubishi Pharma Corporation | Nuevos derivados amida ciclicos. |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
-
2011
- 2011-07-20 TW TW100125662A patent/TWI520949B/zh active
- 2011-07-20 DK DK11810350.6T patent/DK2595485T3/da active
- 2011-07-20 JP JP2013520841A patent/JP2013531073A/ja active Pending
- 2011-07-20 CN CN201611063838.0A patent/CN107007603A/zh active Pending
- 2011-07-20 RU RU2013107378A patent/RU2613201C2/ru active
- 2011-07-20 RU RU2017105262A patent/RU2746871C2/ru active
- 2011-07-20 PL PL11810350T patent/PL2595485T3/pl unknown
- 2011-07-20 ES ES11810350T patent/ES2914120T3/es active Active
- 2011-07-20 WO PCT/US2011/044698 patent/WO2012012543A1/en active Application Filing
- 2011-07-20 US US13/810,775 patent/US20130274290A1/en not_active Abandoned
- 2011-07-20 EP EP11810350.6A patent/EP2595485B1/en active Active
- 2011-07-20 HU HUE11810350A patent/HUE058736T2/hu unknown
- 2011-07-20 CN CN2011800450188A patent/CN103108548A/zh active Pending
- 2011-07-20 CA CA2805904A patent/CA2805904C/en active Active
- 2011-07-20 EP EP22162273.1A patent/EP4070794A3/en active Pending
- 2011-07-20 CA CA3154027A patent/CA3154027A1/en active Pending
- 2011-07-20 KR KR1020137004218A patent/KR101867634B1/ko active IP Right Grant
- 2011-07-20 BR BR112013001302A patent/BR112013001302A2/pt not_active Application Discontinuation
- 2011-07-20 PT PT118103506T patent/PT2595485T/pt unknown
-
2016
- 2016-05-24 US US15/163,385 patent/US20160354357A1/en not_active Abandoned
- 2016-07-07 JP JP2016135208A patent/JP2016199578A/ja active Pending
-
2017
- 2017-11-22 JP JP2017225061A patent/JP6419294B2/ja active Active
-
2020
- 2020-06-29 US US16/914,862 patent/US20210106573A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130129906A (ko) | 2013-11-29 |
| CA2805904A1 (en) | 2012-01-26 |
| US20130274290A1 (en) | 2013-10-17 |
| JP2016199578A (ja) | 2016-12-01 |
| RU2017105262A (ru) | 2019-01-18 |
| EP4070794A3 (en) | 2023-01-18 |
| BR112013001302A2 (pt) | 2017-07-04 |
| EP4070794A2 (en) | 2022-10-12 |
| PL2595485T3 (pl) | 2022-06-20 |
| WO2012012543A1 (en) | 2012-01-26 |
| JP2018065829A (ja) | 2018-04-26 |
| KR101867634B1 (ko) | 2018-06-15 |
| CA2805904C (en) | 2022-06-21 |
| CA3154027A1 (en) | 2012-01-26 |
| RU2613201C2 (ru) | 2017-03-15 |
| HUE058736T2 (hu) | 2022-09-28 |
| US20160354357A1 (en) | 2016-12-08 |
| TWI520949B (zh) | 2016-02-11 |
| JP6419294B2 (ja) | 2018-11-07 |
| RU2746871C2 (ru) | 2021-04-21 |
| EP2595485B1 (en) | 2022-03-16 |
| RU2017105262A3 (da) | 2019-01-18 |
| PT2595485T (pt) | 2022-05-30 |
| CN103108548A (zh) | 2013-05-15 |
| CN107007603A (zh) | 2017-08-04 |
| JP2013531073A (ja) | 2013-08-01 |
| US20210106573A1 (en) | 2021-04-15 |
| RU2013107378A (ru) | 2014-08-27 |
| EP2595485A1 (en) | 2013-05-29 |
| ES2914120T3 (es) | 2022-06-07 |
| TW201211022A (en) | 2012-03-16 |
| EP2595485A4 (en) | 2014-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
| DK3192520T3 (da) | Terapeutiske midler til reducering af niveauerne af parathyreoideahormon | |
| DK3520805T3 (da) | Sammensætninger til behandling af myelofibrose | |
| DK3251678T3 (da) | Benzoxaborolderivater til behandling af bakterieinfektioner | |
| DK3329884T3 (da) | Implanterbar indretning til behandling af glaukom | |
| DK2498771T3 (da) | Anvendelse af bethanechol til behandling af xerostomi | |
| DK2895156T3 (da) | Fremgangsmåde til fremstilling af terapeutiske nanopartikler | |
| DK2853265T3 (da) | Fremgangsmåder til at øge stabiliseringen af hypoxi-inducerbar faktor-1-alpha | |
| DK2504005T3 (da) | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme | |
| DK2701733T3 (da) | Forbindelser til behandling af neuropsykiatriske forstyrrelser | |
| DK2635282T3 (da) | Sammensætninger til behandling af myelofibrose | |
| DK2451796T3 (da) | Tofaanaloger til behandling af dermatologiske lidelser eller tilstande | |
| DK2451482T3 (da) | Kombinationsterapi til behandlingen af diabetes | |
| DE112013002528A5 (de) | Kopfhalterung zur Fixierung des Kopfes von Patienten | |
| DK2595485T3 (da) | Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af sigma-receptormedierede forstyrrelser | |
| EP2566520A4 (en) | METHOD FOR TREATING IL1-MEDIATED INTERFERENCE | |
| DK2903432T3 (da) | Fremgangsmåde til behandling af sædceller til kønsortering | |
| DK3199178T3 (da) | Levende, svækket parvovirus | |
| DK2925317T3 (da) | CFTR-korrektor til behandling af genetiske forstyrrelser, der påvirker tværstribet muskel | |
| DK3495495T3 (da) | Diagnostiske markører til behandling af celleproliferative forstyrrelser med telomeraseinhibitorer | |
| FI20116335A (fi) | Perhappojen tehokkuuden parantaminen | |
| DK2705847T3 (da) | Sammensætning til behandling af psoriasis | |
| DK2807170T3 (da) | Phragmalin-limonoider til behandlingen af seksuel dysfunktion | |
| DK2701707T3 (da) | Fremgangsmåde til behandling af dyskinesi | |
| IT1403587B1 (it) | Composizione per il trattamento di disordini metabolici |